Red blood cell antigen (RBC antigen) (RBC antigen)

Red blood cell (RBC) antigens are a diverse array of proteins, glycoproteins, and glycolipids expressed on the surface of erythrocytes, defining the various blood group systems such as ABO, Rhesus (Rh), Kell, and Duffy (StatPearls: Blood Group Antigens) [1]. These molecules serve critical physiological functions, including maintaining the structural integrity of the cell membrane, acting as ion and gas transporters (e.g., Band 3), and functioning as receptors for chemokines or enzymes (NCBI: NBK2261) [2]. In clinical medicine, RBC antigens are the primary targets of immune-mediated destruction in conditions such as hemolytic disease of the fetus and newborn (HDFN), autoimmune hemolytic anemia (AIHA), and acute or delayed transfusion reactions (PubMed: 29463181) [3]. While they are not traditional targets for small-molecule drug discovery, they are significant in immunotherapy; for example, Rho(D) immune globulin is used to prevent Rh-negative mothers from forming antibodies against the RhD antigen (FDA: RhoGAM) [4]. Furthermore, certain antigens are exploited by pathogens, such as the Duffy antigen, which serves as an essential receptor for Plasmodium vivax malaria parasites (PubMed: 11740493) [5]. Therapeutic challenges include managing alloimmunization and addressing the interference of monoclonal antibodies, like the anti-CD38 drug daratumumab, with blood compatibility testing (PubMed: 26337202) [6]. Understanding the molecular profile of these antigens is critical for transfusion safety, organ transplantation, and managing hematological disorders.

Other names

Blood group antigenErythrocyte antigenRBC surface proteinErythrocyte surface antigen

Passive immunization for the prevention of maternal alloimmunization; monoclonal antibody-mediated targeting of surface proteins for the treatment of hematologic malignancies; inhibition of complement-mediated hemolysis.